SRF-funded Harvard Researchers Explore Cellular Self-destruction as Scleroderma Treatment

Author: Magdalena Kegel
Date Published: January-2018
Source: Scleroderma News

Organ fibrosis in scleroderma patients might be reversed with treatments that allow fibrotic cells to self-destruct, Harvard scientists suggest.

Their study, funded by the SRF, “Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis,” appeared in the journal Science Translational Medicine. It demonstrated that the survival–self-destruction balance of fibrosis-producing myofibroblast cells can be tipped by using a compound now being explored as a cancer treatment.